Technology | March 10, 2010

Statin-Based Drug Lowers Bad Cholesterol

An FDA-approved, cholesterol-lowering medication has been proven to significantly reduce the risk of heart attack, stroke, certain kinds of heart surgeries and chest pain.

Over 29 million people in the United States have been prescribed Lipitor, manufactured by Pfizer. It is one of the most widely studied medicines in the world — with more than 17 years of research, and over 400 ongoing or completed clinical studies encompassing over 80,000 patients.

In clinical studies, Lipitor lowered bad cholesterol significantly more than generic Zocor (simvastatin). Lipitor is a statin that lower cholesterol in your body by blocking an enzyme in the liver. Bodies uses this enzyme to make cholesterol. When less cholesterol is made, the liver uses more of it from the blood, which results in lower levels of cholesterol in the blood.

Along with diet and exercise, Lipitor is proven to:

• Lower LDL ("bad" cholesterol) by 39 to 60 percent
• Lower triglycerides (a type of fat found in the blood) by 19 to 37 percent
• Raise HDL ("good" cholesterol) by 5 percent to 9 percent

Related Content

Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Evolocumab Benefits High-Risk Patients With Established Cardiovascular and Chronic Kidney Disease
News | Pharmaceuticals | October 31, 2018
Amgen announced a new Repatha cardiovascular outcomes study (FOURIER) analysis evaluating the effects of Repatha (...
Jardiance Improves Life Expectancy for Adults With Type 2 Diabetes and Cardiovascular Disease
News | Pharmaceuticals | October 11, 2018
Novel results from the landmark EMPA-REG OUTCOME trial suggest that treatment with Jardiance positively impacts life...
Effect of Daily Aspirin on First-Time Heart Attack and Stroke Risk Inconclusive
News | Pharmaceuticals | September 04, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to...
Overlay Init